Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Lack of Any Association of GST Genetic Polymorphisms with Susceptibility to Ovarian Cancer - a Meta-analysis

  • Han, Li-Yuan (Department of Preventive Medicine, Zhejiang Provincial Key Laboratory of Pathological and Physiological Technology, Medical School of Ningbo University) ;
  • Liu, Kui (Department of Science Research and Information Management, Zhejiang Provincial Center for Disease Control and Prevention) ;
  • Lin, Xia-Lu (Department of Preventive Medicine, Zhejiang Provincial Key Laboratory of Pathological and Physiological Technology, Medical School of Ningbo University) ;
  • Zou, Bao-Bo (Department of Preventive Medicine, Zhejiang Provincial Key Laboratory of Pathological and Physiological Technology, Medical School of Ningbo University) ;
  • Zhao, Jin-Shun (Department of Preventive Medicine, Zhejiang Provincial Key Laboratory of Pathological and Physiological Technology, Medical School of Ningbo University)
  • Published : 2014.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: Epidemiology studies have reported conflicting results between glutathione S-transferase Mu-1 (GSTM1), glutathione S-transferase theta-1 (GSTT1) and glutathione S-transferase pi-1 (GSTP1) and ovarian cancer (OC) susceptibility. In this study, an updated meta-analysis was applied to determine whether the deletion of GSTM1, GSTT1 and GSTP1 has an influence on OC susceptibility. Methods: A published literature search was performed through PubMed, Embase, Cochrane Library, and Science Citation Index Expanded database for articles published in English. Pooled odds ratios (ORs) and 95% confidence intervals (95%CIs) were calculated using random or fixed effects models. Heterogeneity between studies was assessed using the Cochrane Q test and $I^2$ statistics. Sub-group analysis was conducted to explore the sources of heterogeneity. Sensitivity analysis was employed to evaluate the respective influence of each study on the overall estimate. Results: In total, 10 published studies were included in the final analysis. The combined analysis revealed that there was no significant association between GSTM1 null genotype and OC risk (OR=1.01, 95%CI: 0.91-1.12). Additionally, there was no significant association between GSTT1 genetic polymorphisms and OC risk (OR=0.98, 95% CI: 0.85-1.13). Similalry, no significant associations were found concerning the GSTP1 rs1695 locus and OC risk. Meanwhile, subgroup analysis did not show a significant increase in eligible studies with low heterogeneity. However, sensitivity analysis, publication bias and cumulative analysis demonstrated the reliability and stability of the current meta-analysis. Conclusions: These findings suggest that GSTs genetic polymorphisms may not contribute to OC susceptibility. Large epidemiological studies with the combination of GSTM1 null, GSTT1 null and GSTP1 Ile105Val polymorphisms and more specific histological subtypes of OC are needed to prove our findings.

Keywords

References

  1. Arab M, Khayamzadeh M, Mohit M, et al (2009). Survival of ovarian cancer in Iran: 2000-2004. Asian Pac J Cancer Prev, 10, 555-8.
  2. Baxter S W, Thomas E J, Campbell I G (2001). GSTM1 null polymorphism and susceptibility to endometriosis and ovarian cancer. Carcinogenesis, 22, 63-5. https://doi.org/10.1093/carcin/22.1.63
  3. Bell R, Petticrew M, Sheldon T (1998). The performance of screening tests for ovarian cancer: results of a systematic review. Br J Obstet Gynaecol, 105, 1136-47. https://doi.org/10.1111/j.1471-0528.1998.tb09966.x
  4. Booth M, Beral V, Smith P (1989). Risk factors for ovarian cancer: a case-control study. Br J Cancer, 60, 592-8. https://doi.org/10.1038/bjc.1989.320
  5. Buys S S, Partridge E, Black A, et al (2011). Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA, 305, 2295-303. https://doi.org/10.1001/jama.2011.766
  6. Chen B, Zhou Y, Yang P, Wu XT (2010). Glutathione S-transferase M1 gene polymorphism and gastric cancer risk: an updated analysis. Arch Med Res, 41, 558-66. https://doi.org/10.1016/j.arcmed.2010.09.003
  7. Clayton D, Mckeigue P M (2001). Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet, 358, 1356-60. https://doi.org/10.1016/S0140-6736(01)06418-2
  8. Delort L, Chalabi N, Satih S, et al (2008). Association between genetic polymorphisms and ovarian cancer risk. Anticancer Res, 28, 3079-81.
  9. Economopoulos K P, Sergentanis T N, Vlahos N F (2010). Glutathione S-transferase M1, T1, and P1 polymorphisms and ovarian cancer risk: a meta-analysis. Int J Gynecol Cancer, 20, 732-7. https://doi.org/10.1111/IGC.0b013e3181dedeb5
  10. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al (2013). Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer, 49, 1374-403. https://doi.org/10.1016/j.ejca.2012.12.027
  11. Gates M A, Tworoger S S, Terry K L, et al (2008). Talc use, variants of the GSTM1, GSTT1, and NAT2 genes, and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev, 17, 2436-44. https://doi.org/10.1158/1055-9965.EPI-08-0399
  12. Hamajima N, Takezaki T, Tajima K (2002). Allele frequencies of 25 polymorphisms pertaining to cancer risk for Japanese, Koreans and Chinese. Asian Pac J Cancer Prev, 3, 197-206.
  13. Hengstler J G, Kett A, Arand M, et al (1998). Glutathione S-transferase T1 and M1 gene defects in ovarian carcinoma. Cancer Lett, 130, 43-8. https://doi.org/10.1016/S0304-3835(98)00123-2
  14. Hetland T E, Nymoen D A, Emilsen E, et al (2012). MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival. Gynecol Oncol, 126, 460-5. https://doi.org/10.1016/j.ygyno.2012.05.029
  15. Jayde V, Boughton M (2012). The diagnostic journey of ovarian cancer: a review of the literature and suggestions for practice. Contemp Nurse, 41, 5-17. https://doi.org/10.5172/conu.2012.41.1.5
  16. Khokhrin D V, Khrunin A V, Moiseev A A, et al (2012). Association of polymorphisms in glutathione-S-transferase and DNA repair genes with ovarian cancer risk in the Russian population. Genetika, 48, 901-4.
  17. Kurman R J, Shih Ie M (2010). The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol, 34, 433-43. https://doi.org/10.1097/PAS.0b013e3181cf3d79
  18. Lallas T A, Mcclain S K, Shahin M S, Buller R E (2000). The glutathione S-transferase M1 genotype in ovarian cancer. Cancer Epidemiol Biomarkers Prev, 9, 587-90.
  19. Lichtenstein P, Holm N V, Verkasalo P K, et al (2000). Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med, 343, 78-85. https://doi.org/10.1056/NEJM200007133430201
  20. Liu K, Zhang L, Lin X, et al (2013). Association of GST genetic polymorphisms with the susceptibility to hepatocellular carcinoma (HCC) in Chinese population evaluated by an updated systematic meta-analysis. PLoS One, 8, e57043. https://doi.org/10.1371/journal.pone.0057043
  21. Lukanova A, Kaaks R (2005). Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev, 14, 98-107.
  22. Morari E C, Lima A B, Bufalo N E, et al (2006). Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients. J Cancer Res Clin Oncol, 132, 521-8. https://doi.org/10.1007/s00432-006-0099-3
  23. Murthy A K, Kumar V, Suresh K P (2013). Meta-analysis of GSTM1 and GSTT1 polymorphisms and risk of nasopharyngeal cancer. Asian Pac J Cancer Prev, 14, 1697-701. https://doi.org/10.7314/APJCP.2013.14.3.1697
  24. Oliveira C, Lourenco G J, Sagarra R A, et al (2012). Polymorphisms of glutathione S-transferase Mu 1 (GSTM1), Theta 1 (GSTT1), and Pi 1 (GSTP1) genes and epithelial ovarian cancer risk. Dis Markers, 33, 155-9. https://doi.org/10.1155/2012/497692
  25. Peng J, Liu H Z, Zhu Y J (2014). Null Glutathione S-transferase T1 and M1 genotypes and oral cancer susceptibility in China and India-a meta-analysis. Asian Pac J Cancer Prev, 15, 287-90. https://doi.org/10.7314/APJCP.2014.15.1.287
  26. Permuth-Wey J, Sellers T A (2009). Epidemiology of ovarian cancer, Cancer Epidemiol. Springer, 413-37.
  27. Purdie D, Green A, Bain C, et al (1995). Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. survey of women's health study group. Int J Cancer, 62, 678-84. https://doi.org/10.1002/ijc.2910620606
  28. Riman T, Persson I, Nilsson S (1998). Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clin Endocrinol (Oxf), 49, 695-707. https://doi.org/10.1046/j.1365-2265.1998.00577.x
  29. Riman T, Dickman P W, Nilsson S, et al (2002). Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol, 156, 363-73. https://doi.org/10.1093/aje/kwf048
  30. Risch H A, Marrett L D, Howe G R (1994). Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol, 140, 585-97.
  31. Rohani-Rasaf M, Abdollahi M, Jazayeri S, et al (2013). Correlation of cancer incidence with diet, smoking and socio- economic position across 22 districts of Tehran in 2008. Asian Pac J Cancer Prev, 14, 1669-76. https://doi.org/10.7314/APJCP.2013.14.3.1669
  32. Rosenberg L, Palmer J R, Zauber A G, et al (1994). A casecontrol study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol, 139, 654-61.
  33. Sagae S, Mori M, Moore M A (2002). Risk factors for ovarian cancers: Do subtypes require separate treatment in epidemiological studies. Asian Pac J Cancer Prev, 3, 5.
  34. Salinas-Sanchez A S, Sanchez-Sanchez F, Donate-Moreno M J, et al (2011). Polymorphic deletions of the GSTT1 and GSTM1 genes and susceptibility to bladder cancer. BJU Int, 107, 1825-32. https://doi.org/10.1111/j.1464-410X.2010.09683.x
  35. Sarhanis P, Redman C, Perrett C, et al (1996). Epithelial ovarian cancer: influence of polymorphism at the glutathione S-transferase GSTM1 and GSTT1 loci on p53 expression. Br J Cancer, 74, 1757. https://doi.org/10.1038/bjc.1996.626
  36. Spurdle A B, Webb P M, Purdie D M, et al (2001). Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype. Carcinogenesis, 22, 67-72. https://doi.org/10.1093/carcin/22.1.67
  37. Strange R C, Fryer A A (1998). The glutathione S-transferases: influence of polymorphism on cancer susceptibility. IARC scientific publications, 231-49.
  38. Van Nagell J R J, Gallion H H, Pavlik E J, Depriest P D (1995). Ovarian cancer screening. Cancer, 76, 2086-91. https://doi.org/10.1002/1097-0142(19951115)76:10+<2086::AID-CNCR2820761330>3.0.CO;2-L
  39. Wan S M, Lv F, Guan T (2012). Identification of genes and microRNAs involved in ovarian carcinogenesis. Asian Pac J Cancer Prev, 13, 3997-4000. https://doi.org/10.7314/APJCP.2012.13.8.3997
  40. Whalen R, Boyer T D (1998). Human glutathione S-transferases. Seminars in liver disease. Thieme Medical Publishers, 18, 345-58.
  41. Whittmore A S, Harris R, Itnyre J (1992). Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US casecontrol studies II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol, 136, 1184-203.
  42. Ye Z, Song H, Guo Y (2004). Glutathione S-transferase M1, T1 status and the risk of head and neck cancer: a meta-analysis. J Med Genet, 41, 360-5. https://doi.org/10.1136/jmg.2003.016246

Cited by

  1. Interactions between dietary acrylamide intake and genes for ovarian cancer risk vol.32, pp.5, 2017, https://doi.org/10.1007/s10654-017-0244-0